GLAXOSMITHKLINE PLC Form 6-K January 20, 2009

#### FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

**Report of Foreign Issuer** 

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending January 2009

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the

### Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

## Yes No x

# Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of an increase in interests in Ordinary shares purchased at a price of £12.53 per share on 15 January 2009, and Ordinary share ADRs purchased at a price of \$39.43 per ADR on 12 January 2009 in GlaxoSmithKline plc, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 8 January 2009.

	Ordinary shares	<b>ADRs</b>
Mr A P Witty	224.23	
Mr J S Heslop	0.01	
Dr M M Slaoui	65.45	
Mrs C E Bruck Slaoui	20.43	
Mr S M Bicknell	29.20	
Mr J M Clarke	139.42	
Mr M Dunoyer	84.45	
Mr E	84.75	
J Gray		
Mr D Learmouth	0.01	
Mr W C Louv		44.55
Mr D J Phelan		135.99
Dr D Pulman		78.67
Mr D S Redfern	0.38	
Ms C Thomas	0.74	
Mr J R Stéphenne	236.31	

The Company was advised of this information on 19 January 2009

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte Deputy Company Secretary 19 January 2009

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934	, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorised.	

GlaxoSmithKline plc (Registrant)

Date: January 19, 2009

By: VICTORIA WHYTE

-----

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc